CN105232592A - Pharmaceutical composition for treating malignant lymphoma and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating malignant lymphoma and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN105232592A CN105232592A CN201510675296.1A CN201510675296A CN105232592A CN 105232592 A CN105232592 A CN 105232592A CN 201510675296 A CN201510675296 A CN 201510675296A CN 105232592 A CN105232592 A CN 105232592A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- malignant lymphoma
- hibisci mutabilis
- balansae
- cyrtomium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating malignant lymphoma and an application of the pharmaceutical composition. The pharmaceutical composition is prepared from the precipitates of the following traditional Chinese medicinal materials (the precipitates are obtained through a water extract and alcohol precipitate method) in parts by weight: 28-40 parts of cyrtomium balansae, and 52-70 parts of hibiscus mutabilis L. The pharmaceutical composition has an obvious inhibiting effect for the growth of the malignant lymphoma, meanwhile is prepared from the traditional Chinese medicinal materials which are wide in source, low in cost and low in toxic and side effect, and can be developed into the Chinese patent medicine preparation for treating the malignant lymphoma.
Description
Technical field
The invention belongs to technical field of Chinese medicine, in particular to a kind of medical composition and its use for the treatment of malignant lymphoma.
Background technology
Malignant lymphoma is primary in lymph node or other adenoid malignant tumor.In China, lymphoma sickness rate in all malignant tumor rises the fastest, and the speed of annual 5% rises, and has occupied one of ten the highest large malignant tumor of sickness rate.According to statistics, China newly sends out Lymphoma about 8.4 ten thousand people every year, and death toll is more than 4.7 ten thousand, and morbidity crowd's rejuvenation and urbanization trend increase the weight of day by day.Be more common in the young and the middle aged, male patient is more than women.
Malignant lymphoma has a quite heterogeneous large class tumor, although be apt to occur in lymph node, due to lymphoid characteristic distributions, makes lymphoma belong to systemic disease, almost can invade any tissue of whole body and organ.Therefore, the clinical manifestation of malignant lymphoma had both had certain common feature, simultaneously according to different histological type, by invading position and scope also exists again very large difference.C-XF has circle or similar round or lobulated shade, lesion growth can be oppressed bronchus and be caused pulmonary atelectasis, and center of tumor necrosis sometimes forms cavity.Some pulmonary lesions show as diffuse interstitial and sexually revise, and now clinical symptoms is obvious, often have cough, expectoration, breathe hard, dyspnea, and secondary infection can have heating; Malignant lymphoma can invade cardiac muscle and pericardium, shows as pericardial effusion, and lymphoma is invaded cardiac muscle and shown as cardiomyopathy, can have arrhythmia, the performances such as electrocardiographic abnormality; Abdominal part performance spleen is invaded position under the modal diaphragm of HL.Gastrointestinal tract is then the outer diseased region of the modal knot of NHL.After mesentery, peritoneum and iliac fossa lymph node etc. be also the common infringement position of lymphoma; Cutaneous manifestations malignant lymphoma can former or secondary skin be invaded, and is more common in NHL; The bone marrow involvement of bone marrow malignant lymphoma shows as bone marrow and is invaded or merge leukemia, one of many genus terminal stage of a disease performances, and the overwhelming majority is NHL; Manifestations of nervous system, as other performances such as progressive multifocal leukoencephalopathy, subacute necrotic myelopathy, sensation or mobility's peripheral neuropathy and multiple myopathy etc.Malignant lymphoma can also former or tissue, larynx, skeleton and muscular soft tissues etc. after being secondary to brain, epidural, testis, ovary, vagina, cervix uteri, mammary gland, thyroid, adrenal gland, eye socket ball, and complicated clinical manifestation is various.
Although hematopoietic stem cell transplantation or molecular targeted agents treatment malignant lymphoma obtain good achievement (GlassB, KfoessM, BentzM, etal.Dose-escalatedCHOPplusetoposide (MegaCHOEP) followedbyrepeatedstemcelltransplant-tationforprimarytre atmentofaggressivehigh-risknon-Hodgkinlymphoma [J] .Blood, 2006, 107 (8): 3058-3064.), but owing to affecting by the factor such as indication and medical expense, conventional chemotherapy is still current essential therapeutic arsenals.But almost existing chemotherapeutics has the side reactions such as bone marrow depression, alopecia, gastrointestinal reaction, hepatic and renal function damage, just occurrence degree is with to stress face different.Therefore, the lymphoma medicine researching and developing new toxic and side effects little is significant.In the exploratory development of the mankind to cancer therapy drug, Chinese medicine, crude drug more and more highlight its drug effect good, without additive, untoward reaction is few and the advantage such as aboundresources, causes the attention of people.Therefore, find and develop a kind of Chinese Traditional Medicines preventing and treating malignant lymphoma, this seems particularly important.
Summary of the invention
The object of the invention is to by furtheing investigate folk remedy, providing a kind of medicine for the treatment of malignant lymphoma, this medicine has ideal biological activity in suppression lymphoma cell propagation.
The object of the present invention is achieved like this:
Treat a pharmaceutical composition for malignant lymphoma, described pharmaceutical composition is formed through decoction and alcohol sedimentation technique gained precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Cyrtomium balansae (Christ) C. Chr. 28-40 part, Hibisci Mutabilis root 52-70 part.
Further preferably, the pharmaceutical composition for the treatment of malignant lymphoma is formed through decoction and alcohol sedimentation technique gained precipitation by the traditional Chinese medicinal material raw materials of following weight portion as mentioned above: Cyrtomium balansae (Christ) C. Chr. 32-35 part, Hibisci Mutabilis root 58-63 part.
Again further preferably, the pharmaceutical composition for the treatment of malignant lymphoma is formed through decoction and alcohol sedimentation technique gained precipitation by the traditional Chinese medicinal material raw materials of following weight portion as mentioned above: Cyrtomium balansae (Christ) C. Chr. 33 parts, Hibisci Mutabilis root 60 parts.
It should be noted that, in the pharmaceutical composition of preparation treatment malignant lymphoma of the present invention, traditional Chinese medicinal material raw materials Hibisci Mutabilis root wherein selects the dry root of Malvaceae plant Hibisci Mutabilis HibiscusmutabilisL..
The preparation method of pharmaceutical composition of the present invention is: take Cyrtomium balansae (Christ) C. Chr. 28-40 part, Hibisci Mutabilis root 52-70 part, merges and pulverizes; Again above-mentioned graininess medical material is added water and cover powder immersion 0.2-1.0h, then pull out and be placed in extraction element, decoct with water 1-4 time, each amount of water is 10-20 times of medical material total amount, intense fire boils slow fire boiling 1-3h, filter, filtrate reduced in volume is 0.9-1.2 to relative density, adds ethanol and makes volume alcohol content reach 73-77%, stir, leave standstill and make abundant precipitation, filter, gained precipitates after drying and get final product.
Pharmaceutical composition of the present invention adopts water extract-alcohol precipitation to send out and is prepared from, i.e. the Chinese medicine extract B that obtains of decoction and alcohol sedimentation technique gained precipitation; And decoction and alcohol sedimentation technique gained filtrate prepares is Chinese medicine extract A.The present inventor is led to cell assay in vitro research and is found, Chinese medicine extract A does not have obvious inhibitory action to Raji cell in-vitro growth, and Chinese medicine extract B has obvious inhibitory action to Raji cell in-vitro growth, m-dose-dependence when its suppression ratio is, namely under same concentrations, along with drug treating time extends, suppression ratio significantly increases.In addition, under same medicine concentration, the suppression ratio of Chinese medicine extract B group is significantly higher than Chinese medicine extract A group, and difference has statistical significance (P < 0.01).Therefore, another object of the present invention is to provide a kind of pharmaceutical applications, that is: the feedstock composition that Cyrtomium balansae (Christ) C. Chr. and Hibisci Mutabilis root form is deposited in the purposes prepared in the medicine for the treatment of malignant lymphoma through decoction and alcohol sedimentation technique gained.
Compared with prior art, the growth of pharmaceutical composition of the present invention to malignant lymphom cells has obvious inhibitory action, the Chinese crude drug that origin source is wide simultaneously, low cost, toxic and side effects are low is prepared from, and is expected the Chinese patent medicine preparation being developed to treatment malignant lymphoma.
Detailed description of the invention
Be below preparation embodiment of the present invention and effect test example, technical scheme of the present invention and technique effect are further explained.It should be noted that, the traditional Chinese medicinal material raw materials that the embodiment of the present invention adopts has following source: Cyrtomium balansae (Christ) C. Chr. selects the dry rhizome of Dryopteridaceae plant Cyrtomium balansae (Christ) C. Chr. Cyrtomiumbalansae (Christ) C.Chr. [PolypodiumbalansaeChrist].Hibisci Mutabilis root selects the dry root of Malvaceae plant Hibisci Mutabilis HibiscusmutabilisL..
The preparation of embodiment 1 Chinese medicine extract
Take Cyrtomium balansae (Christ) C. Chr. 3.3kg, Hibisci Mutabilis root 6.0kg, merge and pulverize, again above-mentioned graininess medical material is added water and cover powder 2cm, soak 0.5h, then pull out and be placed in extraction element, decoct with water 3 times, 1st 130L that adds water, intense fire boils slow fire boiling 2h, 2nd 120L that adds water, intense fire boils slow fire boiling 1.5h, 3rd 120L that adds water, intense fire boils slow fire boiling 1.5h, collecting decoction, filter, it is 1.10 (65 DEG C of surveys) that filtrate is evaporated to relative density under the condition of 0.08MPa, adding 95% ethanol makes volume alcohol content reach about 75%, stir, leave standstill and make abundant precipitation in 48 hours, filter, gained filtrate decompression recycling ethanol be concentrated into thick paste under 0.08MPa condition, lyophilization, pulverized 100 mesh sieves, obtain Chinese medicine extract dry powder A, gained pellet frozen dry, pulverize 100 mesh sieves, obtained Chinese medicine extract dry powder B.
Embodiment 2 Chinese medicine extract is studied the growth inhibition test of malignant lymphoma Raji cells in vitro
To take the logarithm the people malignant lymphoma Raji cell of trophophase, regulate concentration to 1.5 × 10
5the cell suspension of/mL, be inoculated in 96 orifice plates containing the RPMI1640 culture medium of 10% hyclone, 90 μ L are inoculated in every hole, and often group establishes 4 multiple holes.37 DEG C, 5%CO
2cultivate 12h in incubator, cell is divided into negative control group and experimental group: negative control group does not add any medicine, experimental group adds Chinese medicine extract dry powder A, B of variable concentrations, 10 μ L/ holes.48 are cultivated respectively after each group of dosing, 72h, add the MTT10 μ L/ hole of 5g/L again, continue to cultivate 4h, every hole adds three liquid (SDS of 10%, the isobutanol of 5%, 0.012mol/L hydrochloric acid) 100 μ L cessation reaction, places 12h in 37 DEG C, and microplate reader measures the absorbance (OD value) that wavelength is 492nm, get each class mean, repeat experiment 3 times.Formulae discovery growth inhibition ratio with below: suppression ratio (%)=(negative control group OD value-experimental group OD value)/negative control group OD value × 100%.
Can be found out by the test statistics result of table 1, Chinese medicine extract A does not have obvious inhibitory action to Raji cell in-vitro growth, and Chinese medicine extract B has obvious inhibitory action to Raji cell in-vitro growth, m-dose-dependence when its suppression ratio is, namely under same concentrations, along with drug treating time extends, suppression ratio significantly increases.In addition, under same medicine concentration, the suppression ratio of Chinese medicine extract B group is significantly higher than Chinese medicine extract A group, and difference has statistical significance (P < 0.01), in table 1.
The suppression ratio of the different Chinese medicine extract of table 1 to Raji cell proliferation in vitro compares (%)
Under same time same medicine concentration, Chinese medicine extract B group compares with Chinese medicine extract A group,
*p < 0.01.
Claims (5)
1. treat a pharmaceutical composition for malignant lymphoma, it is characterized in that described pharmaceutical composition is formed through decoction and alcohol sedimentation technique gained precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Cyrtomium balansae (Christ) C. Chr. 28-40 part, Hibisci Mutabilis root 52-70 part.
2. the pharmaceutical composition for the treatment of malignant lymphoma according to claim 1, is characterized in that described pharmaceutical composition is formed through decoction and alcohol sedimentation technique gained precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Cyrtomium balansae (Christ) C. Chr. 32-35 part, Hibisci Mutabilis root 58-63 part.
3. the pharmaceutical composition for the treatment of malignant lymphoma according to claim 2, is characterized in that described pharmaceutical composition is formed through decoction and alcohol sedimentation technique gained precipitation by the traditional Chinese medicinal material raw materials of following weight portion: Cyrtomium balansae (Christ) C. Chr. 33 parts, Hibisci Mutabilis root 60 parts.
4. the pharmaceutical composition of the treatment malignant lymphoma according to claim 1 or 2 or 3, is characterized in that: described traditional Chinese medicinal material raw materials Hibisci Mutabilis root selects the dry root of Malvaceae plant Hibisci Mutabilis HibiscusmutabilisL..
5. the feedstock composition that Cyrtomium balansae (Christ) C. Chr. and Hibisci Mutabilis root form is deposited in the application prepared in the medicine for the treatment of malignant lymphoma through decoction and alcohol sedimentation technique gained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675296.1A CN105232592B (en) | 2015-10-16 | 2015-10-16 | A kind of pharmaceutical composition and its application for treating malignant lymphoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675296.1A CN105232592B (en) | 2015-10-16 | 2015-10-16 | A kind of pharmaceutical composition and its application for treating malignant lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105232592A true CN105232592A (en) | 2016-01-13 |
| CN105232592B CN105232592B (en) | 2019-02-15 |
Family
ID=55030591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510675296.1A Expired - Fee Related CN105232592B (en) | 2015-10-16 | 2015-10-16 | A kind of pharmaceutical composition and its application for treating malignant lymphoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232592B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327309A (en) * | 2007-06-21 | 2008-12-24 | 尧抚人 | Chinese medicine for treating lymph cancer, nasopharyngeal carcinoma and brain cancer |
| CN104825583A (en) * | 2015-05-20 | 2015-08-12 | 陈菊元 | Traditional Chinese medicine dressing for eliminating lymphoma |
-
2015
- 2015-10-16 CN CN201510675296.1A patent/CN105232592B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327309A (en) * | 2007-06-21 | 2008-12-24 | 尧抚人 | Chinese medicine for treating lymph cancer, nasopharyngeal carcinoma and brain cancer |
| CN104825583A (en) * | 2015-05-20 | 2015-08-12 | 陈菊元 | Traditional Chinese medicine dressing for eliminating lymphoma |
Non-Patent Citations (2)
| Title |
|---|
| 张耀钢等: "《观赏苗木育苗关键技术》", 31 August 2003 * |
| 王宁: "《天然药物化学》", 31 July 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105232592B (en) | 2019-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| JP2009515977A (en) | Scutellaria barbata extract for the treatment of cancer | |
| CN102153668A (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN101068558A (en) | Improved anti-cancer treatment | |
| CN105017438A (en) | Divaricate velvetplant root and rhizome polysaccharide and application thereof in preparing medicine and functional food for immune adjustment and tumor resistance | |
| CN102579999B (en) | Medicine for treating carcinous fever and preparation method thereof | |
| Tabin et al. | Medical and medicinal importance of Rheum spp. collected from different altitudes of the Kashmir Himalayan range | |
| CN104256166A (en) | Functional feed for treating bovine bluetongue and preparation method thereof | |
| CN104800174B (en) | A kind of raspberry polysaccharide buccal tablet and application thereof | |
| CN106668041A (en) | Application of rhizoma paridis saponin VI to preparation of anti-lung cancer drugs | |
| CN102696910A (en) | Feed composition and traditional Chinese medicine for preventing and treating avian infectious laryngotracheitis | |
| CN107468999A (en) | A kind of fermentation composition with beauty treatment and eliminating spot function and preparation method thereof | |
| CN104381592A (en) | Feed for the treatment of respiratory diseases in chickens and preparation method thereof | |
| CN105232592A (en) | Pharmaceutical composition for treating malignant lymphoma and application of pharmaceutical composition | |
| CN105030858A (en) | Cynomorium songaricum healthcare tablet and preparation method thereof | |
| CN106072569B (en) | The special dietary seafood of patient's immunocyte balance is adjusted during a kind of chemicotherapy | |
| CN108853469A (en) | Improve the composition and preparation process of mankind spermatozoon vigor and male erection function | |
| CN104922277B (en) | Schisandra chinens P.E is in the application for preparing rescue paraquat poisoning drug | |
| CN103638055B (en) | Polyhachis vicina Roger extract and and antifungal pharmaceutical purposes thereof | |
| CN105288365B (en) | A kind of Chinese medicine composition and application thereof for non-small cell lung cancer postoperative rehabilitation | |
| CN103877411A (en) | Medicinal composition for preventing and treating myocardial fibrosis and application thereof | |
| CN104922268A (en) | Method for extracting active substances from natural plants | |
| CN109010788A (en) | Improve the composition and preparation process of sleep and urine urgency-frequency night pollakiuria disease | |
| CN104045691B (en) | Npas2 protein agonist polypeptide and application thereof | |
| CN108208781A (en) | A kind of reparation hepatic injury, the Cordyceps militaris composition and preparation method and application of strengthen immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190215 Termination date: 20211016 |